Silke Baldewijns

Silke Baldewijns

Auto-generated profile, based on publicly available information

Silke Baldewijns

Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2023 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
PVPaul Vandecruys
Paul Vandecruys
SBSilke Baldewijns
Silke Baldewijns
MSMart Sillen
Mart Sillen
WGWouter Van Genechten
Wouter Van Genechten
PDPatrick Van Dijck
Patrick Van Dijck
Recurrent vulvovaginal candidiasis (RVVC) affects women worldwide and has far-reaching implications for a patient's quality of life. For decades, maintenance treatment using the azole antifungal fluconazole was the preferred treatment. Although efficient in controlling the symptoms, the development of azole resistance and high rates of recurrence after therapy cessation have emerged as significant limitations. Nevertheless, persistent efforts have delivered novel treatment options. Oteseconazole (VT-1161), marketed as VIVJOA, is an oral, tetrazole antifungal with unprecedented specificity toward the fungal lanosterol 14α-demethylase. We reviewed literature data on oteseconazole with a focus on the management of RVVC. Therapeutic options for RVVC are limited, and novel, innovative approaches are needed to treat this debilitating condition. These therapies need to be well-tolerated and prevent RVVC recurrence. The available clinical data show excellent safety and efficacy, with an unprecedentedly low recurrence rate. However, we believe health-care providers should be mindful to monitor for the development of resistance, as this may result in treatment failure. Further, the availability and cost may, like for most novel drugs, affect the widespread clinical implementation of VIVJOA. Altogether, we are convinced that VIVJOA is a significant advance in RVVC management.

17 June 2025 in Research Square
Verified
Preprint
Open access
PDF file
MSMart Sillen
Mart Sillen
DADania El Abyad
Dania El Abyad
NVNina Vreys
Nina Vreys
SBSilke Baldewijns
Silke Baldewijns
IPIlse Palmans
Ilse Palmans
PDPatrick Van Dijck
Patrick Van Dijck
Vulvovaginal candidiasis (VVC) affects millions globally and is characterized by multifactorial immunopathology, with Candida albicans virulence driving disease progression through epithelial tissue damage and neutrophil hyperactivation and dysfunction contributing to disease severity. Here, we explored the multifaceted nature of S. cerevisiae as a live-biotherapeutic to attenuate C. albicans virulence and modulate host immune responses during VVC. We identified an S. cerevisiae isolate that targets multiple aspects of C. albicans virulence, including fungal proliferation, adhesion, and hyphal morphogenesis, collectively impairing biofilm formation and disrupting pathogenic potential. These effects were linked to transcriptional reprogramming in C. albicans , marked by metabolic stress and downregulation of virulence- and biofilm-related genes. Additionally, S. cerevisiae reduced inflammatory responses and neutrophil hyperactivation, while preserving neutrophil antimicrobial functionality. Collectively, this translated to an improved control of infection and dampened VVC-associated hyperinflammation in a murine VVC model. These findings position S. cerevisiae as a promising live biotherapeutic to mitigate C. albicans infection and alleviate hyperinflammation in VVC. Further clinical validation in human cohorts is essential to confirm its therapeutic efficacy. One Sentence Summary: S. cerevisiae attenuates C. albicans virulence and inflammation, offering therapeutic potential for vulvovaginal candidiasis.

26 June 2026 in Nature Communications
Verified
Journal Article
Open access
MSMart Sillen
Mart Sillen
DADania El Abyad
Dania El Abyad
NVNina Vreys
Nina Vreys
SBSilke Baldewijns
Silke Baldewijns
IPIlse Palmans
Ilse Palmans
PDPatrick Van Dijck
Patrick Van Dijck
Vulvovaginal candidiasis (VVC) affects millions of women globally and is characterized by multifactorial immunopathology, with Candida albicans virulence driving disease progression through epithelial tissue damage and neutrophil hyperactivation and dysfunction contributing to disease severity. Here, we explored the multifaceted nature of S. cerevisiae as a live-biotherapeutic to attenuate C. albicans virulence and modulate host immune responses during VVC. We identified an S. cerevisiae isolate (Sc3458) that targets multiple aspects of C. albicans virulence, including fungal proliferation, adhesion, and hyphal morphogenesis, collectively impairing biofilm formation and disrupting pathogenic potential. These effects were linked to transcriptional reprogramming in C. albicans, marked by metabolic stress and downregulation of virulence- and biofilm-related genes. Additionally, S. cerevisiae (Sc3458) reduced inflammatory responses and neutrophil hyperactivation, while preserving neutrophil antimicrobial functionality. Altogether, this translated to an improved control of infection and dampened VVC-associated hyperinflammation in a murine VVC model. These findings position S. cerevisiae strain Sc3458 as a promising candidate live biotherapeutic for VVC treatment. Further clinical validation in human cohorts is essential to confirm its therapeutic efficacy and to assess how Sc3458 performs relative to established market-standard formulations.